We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Increasing affluence, legislative reforms are transforming Poland’s pharmaceutical market

Increasing affluence, legislative reforms are transforming Poland’s pharmaceutical market

October 28, 2013
CenterWatch Staff

Decision Resources has found that Poland’s increasing affluence—as well as its reforms and policy initiatives on healthcare quality, access, privatization and financing—have contributed to growth in the country’s pharmaceutical market during the last decade.

Poland has experienced several years of significant growth in public drug reimbursement expenditure. With a $4.7 billion prescription drug market in 2012, Poland holds strategic importance for multinational companies looking beyond the major pharmaceutical markets for growth opportunities.

However, according to the Poland Market Access Tracker, the market entry of multinationals in Poland is hampered by a number of challenges, including the country’s traditionally low prices for reimbursed drugs, its relatively high patient copayment levels, a large market share for generic drugs and its relatively low spend on healthcare as a percentage of gross domestic product. Additionally, the 2012 Reimbursement of Medicines, Foodstuffs Intended for Particular Nutritional Purposes and Medical Devices Act (Reimbursement Act) has caused radical changes in drug assessment, pricing and reimbursement, and has—in a very short time frame—become one of the most restrictive reimbursement regulations in Europe. After several years of healthy growth in the prescription drugs sector in Poland, the Reimbursement Act drove a sharp 13.4% decline in prescription drug sales in 2012.

“Poland’s initiatives on improving the transparency of drug pricing and reimbursement and on the use of health technology assessment to foster cost-effective use of drugs can ultimately benefit innovators who show the clinical and economic benefits of their therapies to the Polish health system,” said Laurie DiModica, M.S., Decision Resources analyst. “Drug manufacturers operating in Poland now have the opportunity to enter into risk-sharing agreements with the government based on clinical outcomes and expected cost savings. The next few years will be critical to the industry, as the Polish government has signaled its intention to reallocate savings generated through the Reimbursement Act into increasing access to innovative, cost-effective medicines.”

Global News Drug Sponsors

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing